Experience of abrocitinib in atopic dermatitis

Abstract

Atopic dermatitis is an autoinflammatory, genetically determined, itchy disease characterized by a long, relapsing course and a sharp decrease in the patient’s quality of life. Atopic dermatitis is caused by a complex interaction of immune dysregulation, epidermal gene mutations, and multi-environmental factors that affect the skin, causing intense itchy rashes. The disease often occurs among young children and subsequently has age-related clinical features.

Currently, the treatment of atopic dermatitis has a wide range of options, including drugs from the group of small molecules recently registered in the Russian Federation. The drugs are intended for patients with moderate to severe atopic dermatitis. Baricitinib, abrocitinib and upadacitinib as Janus kinase inhibitors from the small molecule group have already demonstrated good tolerability, safety and a pronounced clinical effect in the vast majority of patients with atopic dermatitis in available clinical trials.

The first clinical experience with the use of abrocitinib in adult patients with atopic dermatitis is presented. The interest of the presented clinical cases lies in the demonstration of high clinical efficacy and safety of mono- and combination therapy with the Janus kinase inhibitor abrocitinib. Despite the short period of treatment and observation (4 weeks), objective severity of atopic dermatitis manifestations (SCORAD index >60 points) and sharp decrease in the patients' quality of life (DLQI index >20 points), a reduction of clinical parameters exceeding 60% was achieved at a dose of 200 mg daily. During the whole observation period no adverse clinical reactions or changes in laboratory parameters were registered against the background of abrocitinib administration.

The pilot results of abrocitinib use are encouraging and provide grounds for conducting longer and larger-scale studies to investigate the efficacy of the drug for its inclusion in the combination therapy of patients with moderate to severe atopic dermatitis.

Keywords

аtopic dermatitis / phototherapy / small molecules / abrocitinib / case report

References

[1] Fishbein AB, Silverberg JI, Wilson EJ, Ong PY. Update on atopic dermatitis: Diagnosis, severity assessment, and treatment selection. J Allergy Clin Immunol Pract. 2020;8(1):91–101. EDN: DTYCUJ doi: 10.1016/j.jaip.2019.06.044

[2] Fishbein A.B., Silverberg J.I., Wilson E.J., Ong P.Y. Update on atopic dermatitis: Diagnosis, severity asessment, and treatment selection // J Allergy Clin Immunol Pract. 2020. Vol. 8, N 1. P. 91–101. EDN: DTYCUJ doi: 101016/j.jaip.2019.06.044

[3] Kochergin NG. Skin barrier, xerosis kuperosis. Russ J Allergy. 2013;(6):9–12. EDN: RTLFJD

[4] Кочергин Н.Г. Кожный барьер, ксероз и купероз // Российский аллергологический журнал. 2013. № 6. С. 9–12. EDN: RTLFJD

[5] Pobezhimova OO, Zhestkov AV, Sidorova OS, Kulagina VV. Features of immunopathogenesis of atopic dermatitis. Russ J Allergy. 2020;17(2):74–80. EDN: WANJZA doi: 10.36691/RJA1357

[6] Побежимова О.О., Жестков А.В., Сидорова О.С., Кулагина В.В. Особенности иммунопатогенеза атопического дерматита // Российский аллергологический журнал. 2020. Т. 17, № 2. С. 74–80. EDN: WANJZA doi: 10.36691/RJA1357

[7] Migacheva NB. Atopic dermatitis: An expert review of clinical recommendations. Evraziiskoe Nauchnoe Ob”edinenie. 2021;(9-2):109–113. (In Russ). EDN: ZGWWKV

[8] Мигачева Н.Б. Атопический дерматит: экспертный разбор клинических рекомендаций // Евразийское Научное Объединение. 2021. № 9-2. С. 109–113. EDN: ZGWWKV

[9] Kelexsaeva AA. Atopic dermatitis. Classification and treatment methods. Tendentsii razvitiya nauki i obrazovaniya. 2023;(96-7):24–27. EDN: LPRHFU doi: 10.18411/trnio-04-2023-341

[10] Келехсаева А.А. Атопический дерматит. Классификация и методы лечения // Тенденции развития науки и образования. 2023. № 96-7. С. 24–27. EDN: LPRHFU doi: 10.18411/trnio-04-2023-341

[11] Čepelak I, Dodig S, Pavić I. Filaggrin and atopic march. Biochem Med (Zagreb). 2019;29(2):020501. doi: 10.11613/BM.2019.020501

[12] Čepelak I., Dodig S., Pavić I. Filaggrin and atopic march // Biochem Med (Zagreb). 2019. Vol. 29, N 2. P. 020501. doi: 10.11613/BM.2019.020501

[13] Kochergin NG, Kayumova LN, Zavarykina TM, Asanov AY. Dna methylation profile in the skin of patients with atopic dermatitis. Clin Pract Pediatr. 2019;14(5):66–70. EDN: GHAWB doi: 10.20953/1817-7646-2019-5-66-70

[14] Кочергин Н.Г., Каюмова Л.Н., Заварыкина Т.М., Асанов А.Ю. Особенности профиля метилирования ДНК кожи пациентов с атопическим дерматитом // Вопросы практической педиатрии. 2019. Т. 14, № 5. С. 66–70. EDN: GHAWB doi: 10.20953/1817-7646-2019-5-66-70

[15] Albanova VI, Pampura AN. Atopic dermatitis. Moscow: GEOTAR-Media; 2020. 125 р. (In Russ). doi: 10.33029/9704-5640-8-ATTI-2020-1-144

[16] Альбанова В.И., Пампура А.Н. Атопический дерматит. Москва: ГЭОТАР-Медиа, 2020. 125 с. doi: 10.33029/9704-5640-8-ATTI-2020-1-144

[17] Moosbrugger-Martinz V, Leprince C, Méchin MC, et al. Revisiting the roles of filaggrin in atopic dermatitis. Int J Mol Sci. 2022;23(10):5318. EDN: JMHBKB doi: 10.3390/ijms23105318

[18] Moosbrugger-Martinz V., Leprince C., Méchin M.C., et al. Revisiting the roles of filaggrin in atopic dermatitis // Int J Mol Sci. 2022. Vol. 23, N 10. P. 5318. EDN: JMHBKB doi: 10.3390/ijms23105318

[19] Novikova MS, Kox NV, Mikailova DA, Sergeeva IG. Filaggrin gene mutations and cytokine genes polymorphism in siblings with atopic dermatitis. Russ J Clin Dermatol Venereol. 2021;20(3):43–50. EDN: MBWHCJ doi: 10.17116/klinderma20212003143

[20] Новикова М.С., Кох Н.В., Микаилова Д.А., Сергеева И.Г. Мутации гена филаггрина и полиморфизм генов цитокинов у сибсов с атопическим дерматитом // Клиническая дерматология и венерология. 2021. Т. 20, № 3. С. 43–50. EDN: MBWHCJ doi: 10.17116/klinderma20212003143

[21] Luo L, Luo Y, Xu J, et al. Heterogeneous origin of IgE in atopic dermatitis and psoriasis revealed by B cell receptor repertoire analysis. Allergy. 2022;77(2):559–568. doi: 10.1111/all.15173

[22] Luo L., Luo Y., Xu J., et al. Heterogeneous origin of IgE in atopic dermatitis and psoriasis revealed by B cell receptor repertoire analysis // Allergy. 2022. Vol. 77, N 2. P. 559–568. doi: 10.1111/all.15173

[23] Uchida Y, Park K. Ceramides in skin health and disease: An update. Am J Clin Dermatol. 2021;22(6):853–866. EDN: PAGOBD doi: 10.1007/s40257-021-00619-2

[24] Uchida Y., Park K. Ceramides in skin health and disease: An update // Am J Clin Dermatol. 2021. Vol. 22, N 6. P. 853–866. EDN: PAGOBD doi: 10.1007/s40257-021-00619-2

[25] Chovatiya R. Atopic dermatitis (Eczema). JAMA. 2023;329(3):268. doi: 10.1001/jama.2022.21457

[26] Chovatiya R. Atopic Dermatitis (Eczema) // JAMA. 2023. Vol. 329, N 3. P. 268. doi: 10.1001/jama.2022.21457

[27] Nguyen HL, Trujillo-Paez JV, Umehara Y, et al. Role of antimicrobial peptides in skin barrier repair in individuals with atopic dermatitis. Int J Mol Sci. 2020;21(20):7607. doi: 10.3390/ijms21207607

[28] Nguyen H.L., Trujillo-Paez J.V., Umehara Y., et al. Role of antimicrobial peptides in skin barrier repair in individuals with atopic dermatitis // Int J Mol Sci. 2020. Vol. 21, N 20. P. 7607. doi: 10.3390/ijms21207607

[29] Olisova OYu, Svitich OA, Poddubikov AV, et al. Microbiological assessment of the effectiveness of standard therapy in atopic dermatitis. Vestnik dermatologii i venerologii. 2023;99(3):44–52. EDN: PFBDNT doi: 10.25208/vdv1364

[30] Олисова О.Ю., Свитич О.А., Поддубиков А.В., и др. Микробиологическая оценка эффективности стандартной терапии при атопическом дерматите // Вестник дерматологии и венерологии. 2023. Т. 99, № 3. С. 44–52. EDN: PFBDNT doi: 10.25208/vdv1364

[31] Alkon N, Bauer WM, Krausgruber T, et al. Single-cell analysis reveals innatelymphoid cell lineage infidelity in atopicdermatitis. Allergy Clin Immunol. 2022;149(2):624–639. EDN: NSWFAN doi: 10.1016/j.jaci.2021.07.025

[32] Alkon N., Bauer W.M., Krausgruber T., et al. Single-cell analysis reveals innatelymphoid cell lineage infidelity in atopic dermatitis // Allergy Clin Immunol. 2022. Vol. 149, N 2. P. 624–639. EDN: NSWFAN doi: 10.1016/j.jaci.2021.07.025

[33] Olisova OY. New agent for the treatment of atopic dermatitis. Lechebnoe delo. 2015;(2):63–68. EDN: SZNNIA

[34] Олисова О.Ю. Инновационное средство лечения атопического дерматита // Лечебное дело. 2015. № 2. С. 63–68. EDN: SZNNIA

[35] Zaslavskij DV, Barinova AN, Plavinskij SL, et al. Influence of the cream with filaggrin activity modulator for dry and sensitive skin in children with mild to moderate severity atopic dermatitis on objective indicators of skin barrier function and disease severity indices. Russ J Skin Venereal Dis. 2023;26(1):25–39. EDN: FDEZFD doi: 10.17816/dv122220

[36] Заславский Д.В., Баринова А.Н., Плавинский С.Л., и др. Влияние крема для сухой и чувствительной кожи с модулятором активности филаггрина на объективные показатели барьерной функции кожи и индексы тяжести заболевания у пациентов детского возраста с атопическим дерматитом лёгкой и средней степени тяжести // Российский журнал кожных и венерических болезней. 2023. Т. 26, № 1. С. 25–39. EDN: FDEZFD doi: 10.17816/dv122220

[37] Sidbury R, Davis DM, Cohen DE, et al. Guidelines of care for the management of atopic dermatitis: Section 3. Management and treatment with phototherapy and systemic agents. J Am Acad Dermatol. 2014;71(2):327–349. doi: 10.1016/j.jaad.2014.03.030

[38] Sidbury R., Davis D.M., Cohen D.E., et al. Guidelines of care for the management of atopic dermatitis: Section 3. Management and treatment with phototherapy and systemic agents // J Am Acad Dermatol. 2014. Vol. 71, N 2. P. 327–349. doi: 10.1016/j.jaad.2014.03.030

[39] Puar N, Chovatiya R, Paller AS. New treatments in atopic dermatitis. Ann Allergy, Asthma Immunol. 2020; 26(1):21–31. EDN: XEERXG doi: 10.1016/j.anai.2020.08.016

[40] Puar N., Chovatiya R., Paller A.S. New treatments in atopic dermatitis // Ann Allergy, Asthma Immunol. 2020. Vol. 26, N 1. P. 21–31. EDN: XEERXG doi: 10.1016/j.anai.2020.08.016

[41] Reich K, Thyssen JP, Blauvelt A, et al. Efficacy and safety of abrocitinib versus dupilumab in adults with moderate-to-severe atopic dermatitis: A randomised, double-blind, multicentre phase 3 trial. Lancet. 2022;400(10348):273–282. EDN: OKFNRR doi: 10.1016/S0140-6736(22)01199-0

[42] Reich K., Thyssen J.P., Blauvelt A., et al. Efficacy and safety of abrocitinib versus dupilumab in adults with moderate-to-severe atopic dermatitis: A randomised, double-blind, multicentre phase 3 trial // Lancet. 2022. Vol. 400, N 10348. P. 273–282. EDN: OKFNRR doi: 10.1016/S0140-6736(22)01199-0

[43] Bieber T, Simpson EL, Silverberg JI, et al. Abrocitinib versus placebo or dupilumab for atopic dermatitis. N Engl J Med. 2021;384(12):1101–1112. doi: 10.1056/NEJMoa2019380

[44] Bieber T., Simpson E.L., Silverberg J.I., et al. Abrocitinib versus placebo or dupilumab for atopic dermatitis // N Engl J Med. 2021. Vol. 384, N 12. P. 1101–1112. doi: 10.1056/NEJMoa2019380

[45] Blauvelt A, Silverberg JI, Lynde CW, et al. Abrocitinib induction, randomized withdrawal, and retreatment in patients with moderate-to-severe atopic dermatitis: Results from the JAK1 Atopic Dermatitis Efficacy and Safety (JADE) REGIMEN phase 3 trial. J Am Acad Dermatol. 2022;86(1):104–112. EDN: XSSWTL doi: 10.1016/j.jaad.2021.05.075

[46] Blauvelt A., Silverberg J.I., Lynde C.W., et al. Abrocitinib induction, randomized withdrawal, and retreatment in patients with moderate-to-severe atopic dermatitis: Results from the JAK1 Atopic Dermatitis Efficacy and Safety (JADE) REGIMEN phase 3 trial // J Am Acad Dermatol. 2022. Vol. 86, N 1. P. 104–112. EDN: XSSWTL doi: 10.1016/j.jaad.2021.05.075

[47] The FDA has expanded the indications for the appointment of an oral Janus kinase inhibitor 1. Pediatric Pharmacol. 2023;20(1):92. EDN: PYCALI

[48] FDA расширило показания к назначению перорального ингибитора янус-киназы 1 // Педиатрическая фармакология. 2023. Т. 20, № 1. С. 92. EDN: PYCALI

[49] Eichenfield LF, Flohr C, Sidbury R, et al. Efficacy and safety of abrocitinib in combination with topical therapy in adolescents with moderate-to-severe atopic dermatitis: The JADE TEEN randomized clinical trial. JAMA Dermatol. 2021;157(10):1165–1173. doi: 10.1001/jamadermatol.2021.2830

[50] Eichenfield L.F., Flohr C., Sidbury R., et al. Efficacy and safety of abrocitinib in combination with topical therapy in adolescents with moderate-to-severe atopic dermatitis: The JADE TEEN randomized clinical trial // JAMA Dermatol. 2021. Vol. 157, N 10. P. 1165–1173. doi: 10.1001/jamadermatol.2021.2830

[51] Kubanova AA, Avdienko IN, Bakulev AL, et al. Clinical guidelines for the management of patients with atopic dermatitis. Moscow: Russian Society of Dermatovenerologists and Cosmetologists; 2023. 40 р. (In Russ).

[52] Кубанова А.А., Авдиенко И.Н., Бакулев А.Л., и др. Клинические рекомендации по ведению больных атопическим дерматитом. Москва: Российское общество дерматовенерологов и косметологов, 2023. 40 с.

RIGHTS & PERMISSIONS

Eco-Vector